Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hospital Mater DeiBSP:MATD3 +0.63%83 3-Year EBITDA Growth Rate is 7.70% as of Mar. 2026, which is 56% below its 10-year median of 17.35. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.90 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 528 Healthcare Providers & Services companies, Hospital Mater Dei ranks worse than 55.3% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hospital Mater Dei was 45.70% per year. The lowest was 7.70% per year. And the median was 17.35% per year.
Hospital Mater Dei (BSP:MATD3) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hospital Mater Dei 3-Year EBITDA Growth Rate Related Terms
BSP:MATD3 vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Hospital Mater Dei's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hospital Mater Dei 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hospital Mater Dei's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hospital Mater Dei's 3-Year EBITDA Growth Rate falls into.
Hospital Mater Dei 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.70% mean?
Hospital Mater Dei (BSP:MATD3) has a 3-Year EBITDA Growth Rate of 7.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hospital Mater Dei and its competitors. This is 56% below median its historical median of 17.35. Over the past decade, Hospital Mater Dei's 3-Year EBITDA Growth Rate has ranged from 7.70 to 45.70. According to the industry distribution chart, Hospital Mater Dei ranks #292 out of 528 companies in the Healthcare Providers & Services industry, placing it in the top 55.3%.
Is Hospital Mater Dei's 3-Year EBITDA Growth Rate too high?
Hospital Mater Dei's current 3-Year EBITDA Growth Rate of 7.70% is 56% below median its 10-year median of 17.35. Over the past 10 years, this metric has ranged from a low of 7.70 to a high of 45.70. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Hospital Mater Dei's value of 7.70% is 24.5% below this industry median. Based on the distribution chart, Hospital Mater Dei ranks #292 out of 528 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Hospital Mater Dei ranks #292 out of 528 companies for 3-Year EBITDA Growth Rate. This places Hospital Mater Dei in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Hospital Mater Dei's value of 7.70% is 24.5% below this benchmark. Historically, Hospital Mater Dei's own 3-Year EBITDA Growth Rate has ranged from 7.70 to 45.70 over the past decade. While the company's 10-year median is 17.35 vs. the industry median of 10.20, Hospital Mater Dei has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hospital Mater Dei's current 3-Year EBITDA Growth Rate of 7.70% is 24.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hospital Mater Dei and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital Mater Dei's current 3-Year EBITDA Growth Rate is 7.70%, which is 56% below median its own 10-year median of 17.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$5.90, compared to a current price of R$4.80 — trading 18.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.70%, which is 56% below median its 10-year median of 17.35 and 24.5% below the Healthcare Providers & Services industry median of 10.20. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current 3-Year EBITDA Growth Rate is 7.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?
Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued.
The current stock price of R$4.80 is trading 18.6% below its estimated GF Value™ of R$5.90.
GuruFocus considers Hospital Mater Dei to be Modestly Undervalued.
Key valuation signals for BSP:MATD3:
3-Year EBITDA Growth Rate: 7.70% (56% below median its 10-year median of 17.35)
GF Value™: R$5.90 vs. price of R$4.80 (18.6% below fair value)
Industry Position: 24.5% below the Healthcare Providers & Services median (#292 of 528)
No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score
Get the complete analysis for BSP:MATD3
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MATD3 has been successfully added to your 
